NCT06001788 2025-12-03Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1 Recruiting171 enrolled
NCT07157514 2025-09-10Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLActinium PharmaceuticalsPhase 2/3 Not yet recruiting306 enrolled